Halozyme Therapeutics (Halozyme Therapeutics) Debt-to-Equity

: 17.89 (As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

Halozyme Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.0 Mil. Halozyme Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1,499.2 Mil. Halozyme Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $83.8 Mil. Halozyme Therapeutics's debt to equity for the quarter that ended in Dec. 2023 was 17.89.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Halozyme Therapeutics's Debt-to-Equity or its related term are showing as below:

HALO' s Debt-to-Equity Range Over the Past 10 Years
Min: -6.67 Med: 1.92 Max: 17.89
Current: 17.89

During the past 13 years, the highest Debt-to-Equity Ratio of Halozyme Therapeutics was 17.89. The lowest was -6.67. And the median was 1.92.

HALO's Debt-to-Equity is ranked worse than
99.72% of 1070 companies
in the Biotechnology industry
Industry Median: 0.14 vs HALO: 17.89

Halozyme Therapeutics Debt-to-Equity Historical Data

The historical data trend for Halozyme Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Halozyme Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

4.39

2.63

4.45

8.87

17.89

Halozyme Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity																8.87	22.69	9.91	6.01	17.89

Competitive Comparison

For the Biotechnology subindustry, Halozyme Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Halozyme Therapeutics Debt-to-Equity Distribution

For the Biotechnology industry and Healthcare sector, Halozyme Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Halozyme Therapeutics's Debt-to-Equity falls into.

Halozyme Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Halozyme Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	1499.248)	/	83.808
	=	17.89

Halozyme Therapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	1499.248)	/	83.808
	=	17.89

Halozyme Therapeutics (NAS:HALO) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Halozyme Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Halozyme Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Halozyme Therapeutics (Halozyme Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halozyme Therapeutics Inc (NAS:HALO) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

RV7:Germany

Address

12390 El Camino Real, San Diego, CA, USA, 92130

Website

https://www.halozyme.com

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Executives

Michael J. Labarre	officer: SVP, Chief Technical Officer	11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Helen Torley	director, officer: President and CEO	C/O ONYX PHARMACEUTICALS, INC., 249 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
James M Daly	director	INCYTE CORPORATION EXPERIMENTAL STATION, RTE 141 & HENRY CLAY RD. BLDG E336, WILMINGTON DE 19880
Jeffrey William Henderson	director	7000 CARDINAL PLACE, DUBLIN OH 43017
Nicole Labrosse	officer: SVP, Chief Financial Officer	11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Barbara Gayle Duncan	director	C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES STREET, NEW YORK NY 10013
Matthew L. Posard	director	11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Akiko Moni Miyashita	director	20725 S. WESTERN AVENUE, SUITE 136, TORRANCE CA 90501
Mark Howard Snyder	officer: SVP, General Counsel	11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Matsui Connie	director	3030 CALLAN RD, SAN DIEGO CA 92121
Jean-pierre Bizzari	director	235 LAUREL LN, HAVERFOLD PA 19041
Kenneth J Kelley	director	1331 HILLVIEW DRIVE, MENLO PARK CA 94025
Elaine D Sun	officer: SVP, Chief Financial Officer	11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Masaru Matsuda	officer: SVP, General Counsel	11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Benjamin Hickey	officer: SVP, Chief Commerical Officer	C/O MIRATI THERAPEUTICS, 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA 92121